drugset / Trial / NCT01963195
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of dose escalation of Icotinib in advanced non small cell lung cancer (NSCLC) patients after the therapy of Icotinib, Iressa and Tarceva.
Timeline
- Start
- 2014-02
- Primary completion
- 2018-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icotinib | Small molecule | 250 mg | — |
| Subject | Icotinib | Small molecule | 375 mg | — |
| Subject | Icotinib | Small molecule | 500 mg | — |